Newsletter Signup | Join Community
Genomic testing identifies genetic targets that can be treated with precision cancer medicines avoiding chemotherapy
PARPs and Avastin delay progression when used as maintenance therapy for certain individuals with ovarian cancer.
Understanding PARP inhibitor treatment in ovarian cancer - updated results from the Oct. ESMO 2019 meeting.
Lynparza is an effective treatment for women with newly diagnosed and recurrent BRCA + and other mutated ovarian cancers
Learn how to qualify for SS benefits.
2019 saw the greatest changes in the management of ovarian cancer in 20 years - learn more.
What your DNA reveals and why it’s worth knowing
Answers to frequently asked questions about Ovarian Germ Cell cancers
Answers to frequently asked questions about CA 125.
Combination of novel precision cancer medicines represents future direction of ovarian cancer treatment.
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Stay Current With Ovarian Cancer Treatment Advances & Connect with Others
Hospital and surgeon experience contribute to lower mortality rates and better outcomes for ovarian cancer.
Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…